Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Eczema (Atopic Dermatitis) Clinical Trials

A listing of Eczema (Atopic Dermatitis) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (76) clinical trials

Secukinumab for Treatment of Atopic Dermatitis

This is a randomized, double-blind, pilot study of a total of 44 subjects with AD (22 with intrinsic and 22 with extrinsic AD) consisting of 2 phases. Subjects will be randomized (2:1) to either receive secukinumab 300 mg or placebo via subcutaneous injection using 2 prefilled syringes.

Phase

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

The objective of this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis. The secondary objectives are to evaluate to evaluate adverse event (AE) profiles of DSXS administered to patients with moderate to severe atopic dermatitis.

Phase

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

Phase

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease that affects up to 25% of children and 10% of adults. Atopic skin disease is associated with significant morbidity as well as physical, psychological, and economical quality-of-life impairment. The economical impact of AD and the requirement for family support ...

Phase N/A

To Assess the Safety and Activity of GBR 830 Compared to Placebo in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)

Approximately 40 patients who meet eligibility criteria will undergo baseline assessments and randomize to receive GBR 830 or placebo. Safety and tolerability of GBR 830 will be evaluated in patients with AD/eczema.

Phase

Study Of PF-06817024 In Healthy Subjects In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

The purpose of the study for Part 1 is to evaluate the safety and tolerability of PF-06817024 in healthy subjects. The purpose of the study for Part 2 is to evaluate the safety and tolerability of PF-06817024 in patients with chronic rhinosinusitis with nasal polyps. The purpose of the study ...

Phase

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis

This is a phase 1 and 2 study to assess the safety and efficacy of PAC-14028 cream in children with atopic dermatitis.

Phase

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe AD. Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued ...

Phase

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

This study is a dose escalation study to determine a safe and tolerable dose of ASN002 for people with moderate to severe atopic dermatitis. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and skin biopsies. Subjects will also be assessed for improvement in their ...

Phase

A Study in Subjects With Moderate Atopic Dermatitis

The main objectives of this study are to: - Evaluate the safety and tolerability of ALX-101 Gel 1.5% and 5% when applied topically in subjects with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle - Evaluate the dose-response relationship of ALX-101 Gel 1.5% and 5% when applied topically ...

Phase